Publications - HIV

Stages of pregnancy and HIV affect diagnosis of tuberculosis infection and Mycobacterium Tuberculosis (MTB)-induced immune response: Findings from PRACHITi, a cohort study in Pune, India

Post Date: 
2021-01-11
   |   
Countries: 
India
Publication: 
IJID
Background Accurate tuberculosis infection (TBI) tests are critical for pregnant women, especially those with HIV, who have a high risk of TB disease. Methods We enrolled interferon gamma release assay (IGRA)+ pregnant women with and without HIV in a longitudinal study, followed up at delivery and...

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention

Post Date: 
2020-11-26
   |   
Countries: 
India
United States
Publication: 
The Journal of Antimicrobial Chemotherapy
Background: The use of rifamycin antibiotics for TB prevention carries a risk of detrimental drug-drug interactions with concomitantly used ART. Objectives: To evaluate the interaction of the antiretroviral drug nevirapine in combination with 4 weeks of daily rifapentine and isoniazid for TB...

The burden of anxiety among people living with HIV during the COVID-19 pandemic in Pune, India

Post Date: 
2020-10-23
   |   
Countries: 
India
Publication: 
BMC Public Health
Introduction: Globally, India has the third largest population of people living with HIV (PLHIV) and the second highest number of COVID-19 cases. Anxiety is associated with antiretroviral therapy (ART) nonadherence. It is crucial to understand the burden of anxiety and its sources among Asian...

Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With HIV

Post Date: 
2020-09-30
Publication: 
Clinical Infectious Diseases
Background: IMPAACT P1078, a randomized non-inferiority study designed to compare safety of starting isoniazid preventive therapy (IPT) in women with HIV during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not...

Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping

Post Date: 
2020-09-09
   |   
Countries: 
India
Publication: 
Clinical Pharmacology and Therapeutics
World Health Organization guidelines recommend that individuals living with HIV receive ≥6 months of isoniazid preventive therapy, including pregnant women.

The effect of TB treatment on health-related quality of life for people with advanced HIV

Post Date: 
2020-09-01
   |   
Countries: 
India
Publication: 
International Journal of Tuberculosis and Lung Disease
BACKGROUND: Study A5274 was an open-label trial of people with HIV (PLHIV) with CD4 cell count <50 cells/µL who were randomized to empirical TB treatment vs. isoniazid preventive therapy (IPT) in addition to antiretroviral therapy (ART). We evaluated health-related quality of life (HRQoL) by...

An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus

Post Date: 
2020-08-01
Publication: 
The Journal of Infectious Diseases
Background Chronic kidney disease is a common comorbid condition among persons living with human immunodeficiency virus (PWH). We characterized baseline kidney function in the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) trial cohort. Methods REPRIEVE enrolled PWH with low to...

Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV

Post Date: 
2020-07-28
   |   
Countries: 
India
Publication: 
Clinical Infectious Diseases
944 women with HIV participating in a randomized, double-blind, placebo-controlled study comparing 28 weeks of IPT antepartum versus postpartum, were tested by QuantiFERON-gold-in-tube (QGIT) antepartum and by QGIT and tuberculin skin test (TST) at delivery and postpartum.

A mobile health-facilitated behavioral intervention for community health workers improves exclusive breastfeeding and early infant HIV diagnosis in India: A cluster randomized trial

Post Date: 
2020-07-03
   |   
Countries: 
India
   |   
Clinical Sites: 
BJGMC
Publication: 
Journal of the International AIDS Society
When community health workers used a mobile health intervention with HIV+ women to deliver care, there was a higher uptake of exclusive breastfeeding at two months and early infant HIV diagnosis at six weeks

Trends and gender differences in access to HIV care with scale up of national HIV treatment guidelines in India

Post Date: 
2020-06-24
   |   
Countries: 
India
Publication: 
Journal of the International Association of Providers of AIDS Care
Test and treat is the current global standard, yet sex differences persist in access to HIV care. We assessed the differences in presentation and antiretroviral therapy (ART) uptake by sex and ART-eligibility period among ART-naive adults registered at a public ART center in India. Four ART...

Once-Weekly Rifapentine and Isoniazid (3HP) Among Patients with HIV Taking Dolutegravir-based Antiretroviral Therapy: A Phase I/II Clinical Trial

Post Date: 
2020-06-01
Publication: 
The Lancet HIV
Background Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV. However, a small previous trial of such therapy with dolutegravir in healthy, HIV-...

Acceptability and Feasibility of a Behavioral and Mobile Health Intervention (COMBIND) Shown to Increase Uptake of Prevention of Mother to Child Transmission (PMTCT) Care in India

Post Date: 
2020-05-24
   |   
Countries: 
India
Publication: 
BMC Public Health
A cluster-randomized trial recently demonstrated that an integrated behavioral and mobile technology intervention improved uptake of key components of a Prevention of Mother to Child Transmission (PMTCT) Option B+ program, among HIV- infected pregnant/breastfeeding women in India.

Once-weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Patients With HIV Taking Dolutegravir-Based Antiretroviral Therapy: A Phase 1/2 Trial

Post Date: 
2020-03-30
Publication: 
Lancet HIV
Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV.

TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence

Post Date: 
2020-03-23
Publication: 
Journal of the International AIDS Society
World TB Day viewpoint on the need for more data about TB treatment for pregnant and postpartum women in J Int AIDS Soc by Drs. Jyoti Mathad and Amita Gupta.

HIV, Pregnancy, and Isoniazid Preventive Therapy. Reply

Post Date: 
2020-03-19
   |   
Countries: 
India
Publication: 
The New England Journal of Medicine
Gupta et al. (Oct. 3 issue)1 report a higher incidence of adverse pregnancy outcomes among women with human immunodeficiency virus (HIV) infection who were exposed to isoniazid preventive therapy (IPT) during the second and third trimesters than among those not exposed to IPT during pregnancy. From...

Hepatotoxicity and Liver-Related Mortality in Women of Child-Bearing Potential Living With HIV and High CD4 Counts Initiating Efavirenz-Containing Regimens

Post Date: 
2020-03-12
Publication: 
Clinical Infectious Diseases
Background: Severe hepatotoxicity in people with HIV receiving efavirenz (EFV) has been reported. We assessed the incidence and risk factors of hepatotoxicity in women of child-bearing age initiating EFV-containing regimens. Methods: In the PROMISE trial, ART-naïve pregnant women with HIV and CD4...

High prevalence of late presentation of ART-naïve perinatally infected children for care in Pune, India

Post Date: 
2020-02-19
   |   
Countries: 
India
   |   
Clinical Sites: 
BJGMC
Publication: 
AIDS Care
AIDS Care : There is an urgent need to identify strategies that improve linkage of perinatally infected ART-naïve children to care, and earlier than what is currently observed.

Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV

Post Date: 
2019-12-20
Publication: 
Lancet HIV
Lancet HIV: Dr. Bob Bollinger and colleagues discuss the urgent need and opportunity to include activity against Hepatitis B in formulations of long-acting drugs for HIV prevention and treatment

A parsimonious host inflammatory biomarker signature predicts incident TB and mortality in advanced HIV

Post Date: 
2019-11-25
Publication: 
Clinical Infectious Diseases
BACKGROUND: People with advanced HIV (CD4<50) remain at high risk of TB or death despite the initiation of antiretroviral therapy. We aimed to identify immunological profiles that were most predictive of incident TB disease and death. METHODS: The REMEMBER randomized clinical trial enrolled 850...

Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India

Post Date: 
2019-10-29
   |   
Countries: 
India
   |   
Clinical Sites: 
BJGMC
Publication: 
BMC Infectious Diseases
In this study among people living with HIV, Akshay Gupte and colleagues found that the risk of acquiring tuberculosis was higher in those receiving first-line antiretrovial therapy versus those receiving second-line medications.

Pages